It is worth noting that AZD8055, as an mTOR inhibitor, has shown anti-tumor potential by inhibiting mTORC1 and mTORC2, and its application research involves a variety of cancers such as bladder cancer, colon cancer and cervical cancer [83], but has not yet involved OSCC. This evidence concerns the gene MTOR and urinary bladder cancer.